Feasibility of Gynaecologist Led Lynch Syndrome Testing in Women with Endometrial Cancer by Ryan, Neil A. J. et al.
                          Ryan, N. A. J., Donnelly, L., Stocking, K., Evans, D. G., & Crosbie, E.
J. (2020). Feasibility of Gynaecologist Led Lynch Syndrome Testing in
Women with Endometrial Cancer. Journal of Clinical Medicine, 9(6),
[1842]. https://doi.org/10.3390/jcm9061842
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.3390/jcm9061842
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via MDPI at
https://doi.org/10.3390/jcm9061842. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the





Feasibility of Gynaecologist Led Lynch Syndrome
Testing in Women with Endometrial Cancer
Neil A. J. Ryan 1,2 , Louise Donnelly 3,4 , Katie Stocking 5 , D. Gareth Evans 1,3,6 and
Emma J. Crosbie 2,7,*
1 Division of Evolution and Genomic Medicine, University of Manchester, St Mary’s Hospital,
Manchester M13 9WL, UK; neilryan@nhs.net (N.A.J.R.); gareth.evans@mft.nhs.uk (D.G.E.)
2 Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester,
St Mary’s Hospital, Manchester M13 9WL, UK
3 Nightingale and Prevent Breast Cancer Research Unit, Manchester University NHS Foundation Trust,
Manchester M23 9LT, UK; louise.gorman@manchester.ac.uk
4 NIHR Greater Manchester Patient Safety Translational Research Centre, University of Manchester,
Manchester M13 9PL, UK
5 Centre for Biostatistics, Faculty of Biology, Medicine and Health, University of Manchester,
St Mary’s Hospital, Manchester M13 9WL, UK; katie.stocking@manchester.ac.uk
6 Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust,
Manchester Academic Health Science Centre, Manchester M13 9WL, UK
7 Division of Gynaecology, Manchester University NHS Foundation Trust,
Manchester Academic Health Science Centre, Manchester M13 9WL, UK
* Correspondence: emma.crosbie@manchester.ac.uk; Tel.: +44-(0)161-701-6942
Received: 4 May 2020; Accepted: 11 June 2020; Published: 12 June 2020


Abstract: A barrier to Lynch syndrome testing is the need for prior genetic counselling, a resource
demanding process for both patients and healthcare services. We explored the impact of gynaecologist
led Lynch syndrome testing in women with endometrial cancer. Women were approached before
surgery, on the day of surgery or during routine follow up. Lynch syndrome testing was offered
irrespective of age, family history or tumour characteristics. Women’s reasons for being tested were
explored using the Motivations and Concerns for GeNEtic Testing (MACGNET) instrument. The short
form State-Trait Anxiety Inventory (STAI-6) was used to measure anxiety levels. Only 3/305 women
declined Lynch syndrome testing. In total, 175/220 completed MACGNET and STAI-6 psychological
instruments. The consent process took an average of 7 min 36 s (SD 5 min 16 s) to complete. The
point of care at which consent was taken (before, day of surgery, during follow up) did not influence
motivation for Lynch syndrome testing. Anxiety levels were significantly lower when women were
consented during follow up (mean reversed STAI-6 score 32 vs. 42, p = 0.001). Anxiety levels were
not affected by familial cancer history (p = 0.41). Gynaecologist led Lynch syndrome testing is feasible
and may even be desirable in endometrial cancer, especially when offered during routine follow up.
Keywords: Lynch syndrome; consent; anxiety; germline testing; endometrial cancer
1. Introduction
Endometrial cancer is the most common gynaecological cancer in developed countries and its
incidence is rising [1]. Most cases are linked to lifestyle and reproductive factors but a significant
minority is caused by Lynch syndrome. Lynch syndrome is an autosomal dominant cancer
predisposition syndrome arising from a dysfunctional mismatch repair (MMR) system [2]. Inherited
pathogenic variants in MMR genes MLH1, MSH2 (or EPCAM), MSH6 or PMS2 predispose carriers
to multiple malignancies, particularly endometrial, colorectal and ovarian cancers, which typically
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occur at younger ages than sporadic tumours of the same sites [3]. Endometrial cancer is often the first
manifestation of Lynch syndrome in women, and as such offers an important diagnostic opportunity [4].
Lynch syndrome-associated endometrial tumours are characterized by heavy immune cell infiltrates
and thus are exquisitely sensitive to immunotherapy [5]. Further, a Lynch syndrome diagnosis enables
participation in colorectal surveillance programmes and aspirin chemoprevention, strategies proven
to reduce the risk of dying from subsequent cancers [3,6]. The benefits of diagnosis extend to close
family members, who can access Lynch syndrome testing themselves and engage in risk reducing
reproductive choices and preventive gynaecological surgery [7].
The potential for these interventions to save lives supports routine Lynch syndrome testing for all
endometrial cancer patients, especially because selecting women by age, family history or tumour
characteristics misses cases of Lynch syndrome [8]. The routine use of sequential tumour-based tests to
triage women for definitive germline testing has been proposed as the most effective and cost-effective
method of identifying the 3% of women with Lynch syndrome-associated endometrial cancer [9,10].
Initial tumour-based tests, routinely performed to diagnose, stage and inform individualized treatment
plans, do not require explicit patient consent. However, it is widely held that women undergoing
definitive germline testing should first undergo professional genetic counselling to understand
the implications of testing positive [11]. This requirement is a significant barrier to wide scale
implementation of routine testing, placing a considerable burden on already overstretched genetic
services, yet the majority of women are expected to test negative for Lynch syndrome. Alternative
strategies, including gynaecologist led testing and the referral to genetic services only those women who
test positive for a germline pathogenic variant, have not been studied in Lynch syndrome-associated
endometrial cancer before. The optimal timing for seeking informed consent and its impact on uptake,
anxiety levels and motivation for testing is also not known.
The aim of this study was to assess the feasibility of gynaecologist led Lynch syndrome testing in
women with endometrial cancer. We measured uptake, motivations and anxiety levels associated with
being asked about Lynch syndrome testing as part of women’s routine endometrial cancer care.
2. Materials and Methods
2.1. Participants
Consecutive women with suspected or known endometrial cancer undergoing treatment at a large
specialist gynaecological cancer service in the North West of England were invited to participate in the
Proportion of Endometrial Tumours Associated with Lynch Syndrome (PETALS) study. This study,
described in detail elsewhere [12], offered Lynch syndrome testing to unselected endometrial cancer
patients, irrespective of their age, family history or tumour characteristics. All tumours underwent
microsatellite instability (MSI) testing, immunohistochemistry (IHC) for MMR status and when
MLH1/PMS2 IHC loss was present, targeted MLH1 methylation testing. Women provided a blood
sample at enrolment, however, germline testing was only carried out if tumour triage was positive
(MSI-high or MMR-deficient with normal MLH1 methylation) and/or women were aged ≤50 years
or had a strong personal /family history of Lynch syndrome-associated tumours. The PETALS study
was sponsored by the University of Manchester and approved by the North West Research Ethics
Committee (ref 15/NW/0733). The study was prospectively registered on the Cancer Research UK
clinical trial database (ref 13595).
Women were approached in outpatient clinics before surgery, on the day of surgery or during
routine follow up for endometrial cancer. Written, informed consent for Lynch syndrome testing was
obtained by a gynaecological oncology consultant or senior trainee involved in the patient’s clinical
care. Both underwent bespoke, individualised training with a registered genetic counsellor and clinical
geneticist to learn how to consent women for Lynch syndrome testing. This involved a targeted
one-hour training session and opportunities to observe their clinical practice over two cancer genetic
clinics. Participants were given written information about Lynch syndrome and the implications of
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testing positive were explained, including the increased lifetime risk of cancer, recommendations for
colorectal surveillance, aspirin chemoprevention and cascade testing of family members. Women were
given an appointment with a registered genetic counsellor if they tested positive for a Lynch syndrome
pathogenic variant.
The time taken to consent for Lynch syndrome testing was recorded. The time started when Lynch
syndrome testing was introduced and stopped when the participant signed the consent form. Whether
consent was taken before surgery, on the day of surgery or during routine follow up was recorded.
‘Day of surgery’ included the period between the date of surgery and the fifth post-operative day. The
number of participants who accepted or declined Lynch syndrome testing was recorded.
2.2. Familial and Psychological Assessments
Detailed clinical and family histories were taken from every participant. A positive family history
was defined as one first degree relative, or two second degree relatives with colorectal or endometrial
cancer. Participants were invited to complete an optional validated questionnaire to measure their
motivations and general anxiety state at the time of consenting to Lynch syndrome testing. Motivations
were recorded using the Motivations And Concerns for GeNEtic Testing (MACGNET) instrument [13].
This has five subscales: (1) Gaining knowledge for cancer prevention and obtaining information to
guide medical management (B1–B11); (2) Evaluation of partner’s influence on undergoing genetic
testing (B12–B15); (3) Planning for the future (B16–B18); (4) Ability to cope with testing results (B19–B24);
(5) Fear of discrimination. The fifth subscale, which refers to the impact on healthcare insurance, was
excluded as women were recruited from the National Health Service (NHS) in the UK. The six item
short form State-Trait Anxiety Inventory (STAI-6) was used to measure state anxiety at the time of
consent [14]. The STAI-6 lists six emotional states and asks participants to indicate their degree of
alignment on a four-point scale.
2.3. Statistical Analysis
Descriptive statistics for continuous data were prepared using means and standard deviations
for parametric and medians with interquartile ranges for non-parametric data. For categorical data,
proportions and frequencies were given. Formal comparisons were made using a One-Way ANOVA
or Kruskal–Wallis test for continuous data, and Chi-Squared or Fisher’s Exact Test for categorical
variables. For psychological variables, scores of 0 were treated as missing data. Participants with <50%
missing data had their total subsection score imputed using mean substitution [15]. Where >50% data
were missing, questionnaires were considered incomplete and disregarded. Comparisons were made
between the patient groups using a One-Way ANOVA or Kruskal–Wallis test. A post-hoc pairwise
comparison was carried out using a Bonferroni adjustment where appropriate. The impact of family
history on the degree of anxiety was analysed using a Mann–Whitney U Test. In all analyses, a p-value
of <0.05 was considered statistically significant. Statistical analyses were carried out using Stata 14
(StataCorp. 2015. Stata Statistical Software: Release 14. StataCorp LP, College Station, TX, USA) and
GraphPad Prism version 7.0a for Mac OS (GraphPad Software, La Jolla, CA, USA).
3. Results
3.1. Study Participants
In total, 305 women with endometrial cancer were offered Lynch syndrome testing (Figure 1).
Three patients declined because they were anxious about their cancer diagnosis and impending surgery;
all three had been invited to participate on the day of their hysterectomy. One woman changed her
mind and enrolled in the study after surgery. One of the remaining two died shortly after surgery and
the other was lost to follow up. Both were over 80 years of age and had no living first degree relatives.





























Figure 1. Study flow diagram. Footnote. * Three women initially declined Lynch syndrome testing
however one later changed her mind.
The final study population comprised 300 women with a median age and BMI of 65 years
(range 25, 88), and 31 kg/m2 (range 17, 70), respectively. Their ethnicity reflected that of the North
West of England with 83% White, 11% Asian, 3% Black and 3% other. The final pathology showed
atypical hyperplasia (2.3%), endometrioid (72%), serous (9.3%), clear cell (4.3%), carcinosarcoma (7%),
mixed (3.7%) or dedifferentiated (1.7%) endometrial cancer. The majority were low grade (2.3% grade 0,
44.7% grade 1, 19.3% grade 2 and 33.7% grade 3) early stage tumours (2.3% stage 0, 74% stage 1, 12.3%
stage 2, 10.7% stage 3, 0.7% stage 4). Eighty women did not receive a MACGNET or STAI-6 instrument
to complete. Reasons included elapsed patient car parking time or transport pressures (n = 37), no
available translator (n = 11) and clinic time pressures (n = 32). There was no significant difference in
the baseline characteristics of those who were offered instruments and those who were not.
3.2. Time Taken to Consent for Lynch Syndrome Testing
The average time taken to consent for Lynch syndrome testing was 8 min (SD 5 min 20 s). There
were five outliers (ROUT method [16] Q = 0.2%); on removing these, the average time taken was
7 min 36 s (SD 5 min 16 s). The average time taken to consent (once outliers were removed) for Lynch
syndrome testing when this was done before surgery, on the day of surgery or during follow up was
6 min 29 s, 3 min 58 s and 10 min 18 s, respectively. Taking consent during follow up took significant
longer than before or on the day of surgery (p ≤ 0.0001 and p ≤ 0.0001, respectively) because women
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asked more questions. Women over 60 years of age took less time to consent to testing than those
under 60 years, with an average time of 6 min 54 s versus 8 min 13 s, respectively (p = 0.0003). Those
with a positive family history did not differ than those without, taking 7 min 12 s and 7 min and 52 s to
consent to testing, respectively (p = 0.3). Only one patient requested professional genetic counselling
before agreeing to Lynch syndrome testing. Prior to this she had spent 48 min discussing such testing
with the gynaecologist. Unfortunately, the duration of the discussion with the genetics counsellor was
not recorded.
3.3. Baseline Characteristics of the Cohorts
Overall, 175 women completed the MACGNET and STAI-6 instruments (Figure 1). This included
women consented before (n = 34), on the day of surgery (n = 50) and in follow up (n = 91). There was
no significant difference in participant age, BMI, ethnicity or family history of cancer between these
three groups (all p > 0.05). There were also no significant differences between the women who were
and were not offered the questionnaire, nor between those who completed and failed to complete the
questionnaire in age, BMI, ethnicity or family history of cancer (all p > 0.05).
3.4. Motivations for Testing
The reasons women gave for undergoing Lynch syndrome testing did not differ according to
when they were asked, whether that be before, on the day of surgery or in follow up (Table 1). Most
women were motivated to be tested in order to protect their family.
Table 1. MACGNET scores exploring participants’ motivations for undergoing Lynch syndrome testing.
Questionnaire Subsection Before Surgery (n = 34) Day of Surgery (n = 50) In Follow Up (n = 91) p Value




















Results presented as mean score (standard deviation), minimum-maximum score, analysed by One-Way ANOVA.
† Results presented as median (interquartile range), minimum-maximum score, analysed by Kruskal–Wallis
statistical test.
3.5. Anxiety about Testing
Anxiety levels were significantly lower when women were approached about Lynch syndrome
testing in follow up [mean reversed STAI-6 score 32.1 (SD 11.8, range 20–70)] than before surgery
[mean reversed STAI-6 score 42.0 (SD 14.9, range: 20–73.3)] or on the day of surgery [mean reversed
STAI-6 score 42.2 (SD 15.1, range: 20–80)] (One-way ANOVA p < 0.001) (Figure 2).
Detailed family history was available for 173/175 participants. Two women were adopted and
did not know their biological family. Of the 173 participants, 147 (85%) had no family history and
26 (15%) had a positive family history. The median reversed STAI-6 score for women with no family
history was 36.7 (range 20–80) compared to 31.7 (range: 20–70) for those with a positive family history.
The trend was for women without a family history to be more anxious about Lynch syndrome testing,
although this was not statistically significant (Mann–Whitney p = 0.41) (Figure 2).
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Figure 2. Reversed STAI-6 scores according to (A) when women were approached about Lynch 
syndrome testing and (B) their family history of cancer. 
Detailed family history was available for 173/175 participants. Two women were adopted and 
did not know their biological family. Of the 173 participants, 147 (85%) had no family history and 26 
(15%) had a positive family history. The median reversed STAI-6 score for women with no family 
history was 36.7 (range 20–80) compared to 31.7 (range: 20–70) for those with a positive family 
history. The trend was for women without a family history to be more anxious about Lynch 
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Thirteen of the 300 women in this study tested positive for Lynch syndrome. All were offered 
and received formal genetic counselling to discuss the implications of their diagnosis and 
opportunities to reduce their future cancer risk. Cascade Lynch syndrome testing was offered to at 
risk family members. At 12 months after the close of this study, 16 family members had tested 
positive, 16 negative and 3 had declined Lynch syndrome testing. There was no correlation between 
the timing of consent for Lynch syndrome testing and the success of cascade testing. 
4. Discussion 
Here we present the first study of gynaecologist led Lynch syndrome testing in women with 
endometrial cancer. The overwhelming majority of women (99%) accepted germline testing without 
the need for face-to-face professional genetic counselling. Women were motivated to undergo Lynch 
syndrome testing to protect their family, irrespective of whether they were approached before, at the 
time of surgery or in follow up after treatment for endometrial cancer. Anxiety scores were 
significantly lower when Lynch syndrome testing was sought during follow up but was not affected 
by family history status. Interestingly, the time taken to discuss testing and obtain written, informed 
consent was reduced if carried out in the pre-surgical setting. 
The uptake of Lynch syndrome testing was much higher than previously reported [17–19]. This 
may reflect the NHS setting of our study wherein healthcare is publically funded and the personal 
implications for Lynch syndrome testing do not include raised insurance premiums. Only two 
women declined testing, principally because they were too anxious about their recent cancer 
diagnosis and impending hysterectomy. This is consistent with previous work examining uptake of 
genetic testing by parents of children with cancer [20]. Our findings are important because poor 
uptake of germline testing has led authors to call for caution regarding the implementation of 
universal Lynch syndrome testing in cancer populations [21][[22]. Our study suggests that uptake is 
unlikely to be a significant barrier to gynaecologist led Lynch syndrome testing in the UK. 
It took a little less than 8 min to discuss and obtain written, informed consent for Lynch 
syndrome testing in this study. This included time taken to explain the research proposal and for 
women to ask questions regarding participation in the study. The practicalities of incorporating 
consent into routine clinical care therefore needs further exploration, but our data suggest that 
allowing an extra 10 min or so in the setting of a routine gynaecology clinic should suffice. Whilst 
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3.6. Lynch Syndrome Testing Outcomes
Thirteen of the 300 women in this study tested positive for Lynch syndrome. All were offered and
received formal genetic counselling to discuss the implications of their diagnosis and opportunities to
reduce their future cancer risk. Cascade Lynch syndrome testing was offered to at risk family members.
At 12 months after the close of this study, 16 family members had tested positive, 16 negative and 3
had declined Lynch syndrome testing. There was no correlation between the timing of consent for
Lynch syndrome testing and the success of cascade testing.
4. Discussion
Here we present th first study of gynaecologist led Lynch syndrome testing in women with
end metrial cancer. The ove whelming majority of women (99%) accepted g rmline testing with u
the need for face-to-face professional gen tic counselling. Women were mot vated to undergo Lynch
syndrome testing to protect their family, irrespective of whether they w re pproach d before, at the
ime of surgery or in follow up after treat ent for endometrial ancer. Anxiety scores were significantly
lower when Lynch syndrome testing was sought during follow up but was not affected by family
history status. Interestingly, the time taken to discuss testing and obtain written, informed consent was
reduced if carried out in the pre-surgical setting.
The uptake of Lynch syndrome testing was much higher than previously reported [17–19]. This
may reflect the NHS setting of our study wherein healthcare is publically funded and the personal
implications for Lynch syndrome testing do not include raised insurance premiums. Only two women
declined testing, principally because they were too anxious about their recent cancer diagnosis and
impending hysterectomy. This is consistent with previous work examining uptake of genetic testing
by parents of children with cancer [20]. Our findings are important because poor uptake of germline
testing has led authors to call for caution regarding the implementation of universal Lynch syndrome
testing in cancer populations [21,22]. Our study suggests that uptake is unlikely to be a significant
barrier to gynaecologist led Lynch syndrome testing in the UK.
It took a little less than 8 min to discuss and obtain written, informed consent for Lynch syndrome
testing in this study. This included time taken to explain the research proposal and for women to
ask questions regarding participation in the study. The practicalities of incorporating consent into
routine clinical care therefore needs further exploration, but our data suggest that allowing an extra
10 min or so in the setting of a routine gynaecology clinic should suffice. Whilst not trivial, since
routine gynaecology clinics allocate 10–20 min/patient in the UK [23], it does mean that genetic
counselling can be reserved for women who test Lynch syndrome positive. Thus the net resource
implications are cost saving when compared to the traditional approach of genetic counsellors being
the sole arbiters of germline testing [24]. There are implications for training; most gynaecologists
are unfamiliar with discussing Lynch syndrome testing but good quality counselling is important to
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avoid misunderstandings, dissatisfaction and poor outcomes. We undertook formal training with
genetic counsellors with expertise in the management of Lynch syndrome testing before consenting
participants for this study.
Germline testing without prior genetic counselling has been advocated for other cancer
predisposition syndromes [25], however, formal genetic counselling may reduce testing anxiety [26].
The average STAI-6 score for women approached during follow up in our study (32.1 SD 11.8) was
lower than that reported by others when professional genetic counselling had been used. The work
of Cull et al., Brain et al. and Watson et al. reported post genetic counselling STAI-6 scores of 33.7
(SD 9.8), 34.3 (SD 10.8) and 35.2 (SD 10.8), respectively [27–29]. It should be noted that our STAI-6
scores were significantly higher when women were approached shortly after diagnosis or at the time
of hysterectomy. This infers that gynaecology led Lynch syndrome testing is feasible and does not
cause unnecessary anxiety compared to the traditional model of prior referral for genetic counselling,
so long as women are approached during follow up. Before surgery, they are already highly anxious
and seemingly less receptive to discussions about hereditary risk and their future health. This finding
is supported by previous work showing that highly anxious women were less likely to understand the
information given to them about genetic risk; this in turn could be detrimental to their ability to give
informed consent for testing [30].
Women were motivated to undergo Lynch syndrome testing to protect their family members and
engage in prevention interventions. This was consistent whether consent was taken before surgery, on
the day of surgery or during routine follow up. Although it did not reach significance, the MACGNET
scores relating to prevention increased in women who were approached about Lynch syndrome testing
during endometrial cancer follow up. This seems logical and adds further support to consenting
women for Lynch syndrome testing after treatment, when they are better able to focus on future
implications of having a cancer predisposition syndrome.
The strengths of our work include its novelty, the large number of women recruited and use of
validated psychological instruments to identify motivators and stressors associated with gynaecologist
led Lynch syndrome testing. Embedded in a non insurance-based healthcare system, our study
provides an accurate measure of uptake unencumbered by any financial implications of being tested for
a genetic condition. Limitations of our work include failure to offer questionnaires to all participants
and incomplete responses from many. This may have introduced selection bias if responders were
systematically different to non responders. Overall, 175 women provided complete responses and they
did not differ from non responders in terms of key baseline characteristics; this provides reassurance
that selection bias was minimal. The generalizability of our results to other Lynch syndrome-associated
cancers, hereditary cancer predisposition syndromes and healthcare settings is unclear. Indeed,
Balmaña et al. found significant differences in motivators for testing for different cancer predisposition
syndromes, noting that individuals tested for Lynch syndrome were much more likely to be motivated
by the potential to manage their future cancer risk than those tested for hereditary breast and ovarian
syndrome (HBOS) [13,25].
5. Conclusions
Mainstream Lynch syndrome testing in endometrial cancer enables individualised treatment
and provides opportunities to guard against future cancer by both the proband and her family
members. Gynaecologist led testing is feasible and appears to be acceptable to women, especially
when offered during routine follow up. Our work investigating cost effectiveness of gynaecologist led
Lynch syndrome testing reveals cost savings that further strengthen the Manchester approach [24].
More research is now needed to confirm its effectiveness, including formal analysis of how well
gynaecologists substitute for genetic counselors when consenting women for Lynch syndrome testing.
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